United States

Hisamitsu Pharmaceutical Co Inc (HTSUF.PK)

HTSUF.PK on OTC Markets Group - US Other OTC and Grey Market

Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Hisamitsu Pharmaceutical repurchases 840,000 shares in October
Friday, 4 Nov 2016 02:08am EDT 

Hisamitsu Pharmaceutical Co Inc <4530.T>: Says it repurchased 840,000 shares for 4,520,864,000 yen in total from Oct. 18 to Oct. 31 . Says this was part of the share repurchase plan announced on April 8 .Says it repurchased 840,000 shares in total as of Oct. 31.  Full Article

Hisamitsu Pharmaceutical unit assigns rights for Brisdelle Capsules and Pexeva Tablets
Tuesday, 26 Jul 2016 03:12am EDT 

Hisamitsu Pharmaceutical Co Inc <4530.T>:Says its U.S.-based unit, Noven Pharmaceuticals, Inc., has reached agreement to assign rights of approval for manufacture, commercialization and associated intellectual property for Brisdelle(Paroxetine) Capsules, 7.5 mg and Pexeva(Paroxetine Mesylate) Tablets to Sebela International Limited.  Full Article

Hisamitsu Pharmaceutical says private placement of 1 mln treasury stocks
Friday, 8 Jul 2016 02:11am EDT 

Hisamitsu Pharmaceutical <4530.T>: Says it will distribute 1 million shares of its treasury common stock at 1 yen per share through private placement to The Master Trust Bank of Japan, Ltd. on Aug. 19 .Says it will raise 1 million yen in total through private placement.  Full Article

Hisamitsu Pharmaceutical sees sales down 4 pct to JPY 155 bln for FY 2017 - Nikkei
Monday, 27 Jun 2016 01:04pm EDT 

Nikkei: Hisamitsu Pharmaceutical's operating profit apparently took a 13 pct hit for the march-May Quarter - Nikkei . Hisamitsu Pharmaceutical forecasts sales falling 4 pct to 155 billion yen for the year ending February 2017 - NIKKEI .Hisamitsu Pharmaceutical likely earned around 5 bln yen ($49.2 mln) in profit for march-may quarter on a group basis - Nikkei.  Full Article

HISAMITSU PHARMACEUTICAL to issue year-end dividend for FY 2016
Friday, 8 Apr 2016 02:00am EDT 

HISAMITSU PHARMACEUTICAL CO INC:To issue a year-end dividend of 41 yen per share to all the shareholders of record as of Feb. 29, for FY ended Feb. 2016.Payment date May 27.Says latest dividend forecast was 40 yen per share.  Full Article

HISAMITSU PHARMACEUTICAL announces private placement of treasury stock; to repurchase shares
Friday, 8 Apr 2016 02:00am EDT 

HISAMITSU PHARMACEUTICAL CO INC:To distribute 1,000,000 shares of its treasury common stock at 1 yen per share through private placement to The Master Trust Bank of Japan, Ltd.To raise 1 million yen in total through private placement.Says it will repurchase up to 2,000,000 shares of its common stock, representing a 2.36 pct stake by Dec. 31.Share repurchase price is 12,000,000,000 yen in total.  Full Article

HISAMITSU PHARMACEUTICAL amends consolidated mid-year outlook for FY 2016
Wednesday, 30 Sep 2015 12:30am EDT 

HISAMITSU PHARMACEUTICAL CO INC:Says the company lowered the consolidated mid-year outlook for revenue to 82,400 mln yen from 83,300 mln yen for the fiscal year ending Feb. 2016.Operating profit forecast increased to 14,500 mln yen from 12,700 mln yen.Ordinary profit forecast increased to 14,600 mln yen from 13,000 mln yen.Net profit forecast increased to 9,400 mln yen from 8,500 mln yen.Earnings per share increased to 109.72 yen from 99.22 yen.Says profit outlook raised due to the increased proportional division for the general cost and expenses.  Full Article

Mylan NV confirms patent challenge relating to Minivelle from Noven Pharmaceuticals and HISAMITSU PHARMACEUTICAL CO Inc
Tuesday, 5 May 2015 01:15pm EDT 

Mylan NV:Confirmed that it and its subsidiaries Mylan Pharmaceuticals Inc. and Mylan Technologies Inc. have been sued by Noven Pharmaceuticals Inc. and Hisamitsu Pharmaceutical Co., Inc., in connection with the filing of an Abbreviated New Drug Application (ANDA).with the U.S. Food and Drug Administration (FDA) for Estradiol Transdermal System, USP, 'Twice-Weekly' 0.0375 mg/day, 0.05 mg/day, 0.075 mg/day and 0.1 mg/day.This product is the generic version of Minivelle, which is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause and the prevention of postmenopausal osteoporosis.The plaintiffs filed suit against the Mylan companies in the United States District Court in the District of Delaware.  Full Article

More From Around the Web

BRIEF-Hisamitsu Pharmaceutical completes 2 mln shares' repurchase for 11.15 bln yen

* Says it completed repurchase of 2 million shares as scheduled on April 8, for 11.15 billion yen in total